Blood pressure control in the year following coronary events

International Journal of Cardiology

Volumn 130, Issue 2, 2008, Pages 205-210

  Müller Nordhorn, Jacqueline ^a   Völler, Heinz ^b   Pfennig, Andrea ^a   Binting, Sylvia ^a   Krobot, Karl J ^c   Willich, Stefan N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Rehabilitation Center for Cardiovascular Diseases   (Germany)

^c MSD Sharp and Dohme GmbH   (Germany)

Author keywords

Blood pressure; Coronary heart disease; Diabetes; Secondary prevention

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETIC PATIENT; FEMALE; FOLLOW UP; GERMANY; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; EXERCISE THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 54949153787     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.08.042     Document Type: Article

References (35)

1. Gohlke H., Kubler W., Mathes P., et al. Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group. Z Kardiol 90 (2001) 148-149
2. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
3. http://www.paritaet.org/hochdruckliga/Hypertonie-Leitlinien05.pdf. Deutsche Hochdruckliga. 2006.
4. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss 97 (2004) 1019-1030
5. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 (2003) 987-1003
6. Psaty B.M., Lumley T., Furberg C.D., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289 (2003) 2534-2544
7. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
8. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
9. Rashid P., Leonardi-Bee J., and Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 34 (2003) 2741-2748
10. Staessen J.A., Wang J.G., and Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 (2001) 1305-1315
11. Vijan S., and Hayward R.A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138 (2003) 593-602
12. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 357 (2001) 995-1001
13. Persson M., Carlberg B., Mjorndal T., Asplund K., Bohlin J., and Lindholm L. 1999 WHO/ISH Guidelines applied to a 1999 MONICA sample from northern Sweden. J Hypertens 20 (2002) 29-35
14. Hanon O., Anagnostopoulos K., Franconi G., Amah G., Safar M., and Girerd X. Are the 1999 World Health Organization-International Society of Hypertension recommendations applicable to clinical practice?. Arch Mal Coeur Vaiss 93 (2000) 953-957
15. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 19 (1998) 1434-1503
16. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17 (1999) 151-183
17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
18. Schrier R.W., Estacio R.O., Esler A., and Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (2002) 1086-1097
19. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998) 1755-1762
20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
21. Willich S.N., Muller-Nordhorn J., Kulig M., et al. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. Eur Heart J 22 (2001) 307-313
22. Muller-Nordhorn J., Roll S., and Willich S.N. Comparison of the short form (SF)-12 health status instrument with the SF-36 in patients with coronary heart disease. Heart 90 (2004) 523-527
23. Muller-Nordhorn J., Kulig M., Binting S., Voller H., Krobot K.J., and Willich S.N. Regional variation in medication following coronary events in Germany. Int J Cardiol 102 (2005) 47-53
24. Phillips L.S., Branch W.T., Cook C.B., et al. Clinical inertia. Ann Intern Med 135 (2001) 825-834
25. Steinman M.A., Fischer M.A., Shlipak M.G., et al. Clinician awareness of adherence to hypertension guidelines. Am J Med 117 (2004) 747-754
26. Haynes R.B., Yao X., Degani A., Kripalani S., Garg A., and McDonald H.P. Interventions to enhance medication adherence. Cochrane Database Syst Rev (2005) CD000011
27. Houston Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102 (1997) 43-49
28. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
29. Grossman E., Messerli F.H., and Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal?. Arch Intern Med 160 (2000) 2447-2452
30. Fuller J., Stevens L.K., Chaturvedi N., and Holloway J.F. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. Cochrane Database Syst Rev (2000) CD002188
31. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
32. Vittinghoff E., Shlipak M.G., Varosy P.D., et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138 (2003) 81-89
33. Bakris G.L. The importance of blood pressure control in the patient with diabetes. Am J Med 116 suppl (2004) 30-38
34. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64 (2004) 2537-2565
35. Rauch B., Schneider S., Gitt A.K., et al. Short-term cardiac rehabilitation after myocardial infarction- results from the acute coronary syndrome registry. Eur Heart J 26 (2005) 3033 [suppl]